Ngenla ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - hypofÝzy a hypotalamickÝch hormÓny a ich analÓgy - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofýzové a hypotalamické hormóny a analógy - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Elfabrio ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

elfabrio

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabryho choroba - iné alimentárny trakt a metabolizmus výrobky, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).